Abstract | BACKGROUND: AIMS: METHODS: A randomised, double-blind, placebo-controlled, parallel-group, multicentre, 2-week treatment study of FFNS 110 μg once and twice daily was undertaken in adults/adolescents. RESULTS: A statistically significant reduction was seen in the daily major symptoms score, a composite score of three individual symptoms (nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip on a 0-3 scale) by both FFNS doses compared with placebo (least square mean differences vs. placebo of -0.386 (p=0.008) and -0.357 (p=0.014) for once daily and twice daily FFNS, respectively). The differences in median times to symptom improvement were not statistically significant between each dose of FFNS (7 days) and placebo (8 days). There were no treatment differences in antibiotic use for possible fulminant bacterial rhinosinusitis (3% in each group). The safety profile of FFNS was similar to placebo. CONCLUSIONS: FFNS reduces symptoms of uncomplicated ARS compared with placebo and is well tolerated, providing support for withholding antibiotics in selected patients.
|
Authors | Paul K Keith, Andrzej Dymek, Oliver Pfaar, Wytske Fokkens, Suyong Yun Kirby, Wei Wu, Cindy Garris, Nazli Topors, Laurie A Lee |
Journal | Primary care respiratory journal : journal of the General Practice Airways Group
(Prim Care Respir J)
Vol. 21
Issue 3
Pg. 267-75
(Sep 2012)
ISSN: 1475-1534 [Electronic] England |
PMID | 22614920
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Nasal Sprays
- fluticasone furoate
|
Topics |
- Acute Disease
- Adult
- Androstadienes
(administration & dosage)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Male
- Nasal Sprays
- Rhinitis
(drug therapy)
- Sinusitis
(drug therapy)
|